GALDERMA GRP AG
179,20€
+2,10 (+1,19%)
30.04.2026, 22:59:40 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +337,82 +1,41% 24.292,38
- MDAX ® +579,17 +1,93% 30.589,95
- TecDAX ® +72,21 +1,99% 3.697,16
- E-STOXX 50 ® ±0,00 ±0,00% 5.881,51
- NASDAQ 100 +258,24 +0,94% 27.710,36
- HANG SENG -332,14 -1,27% 25.776,53
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 179,20€ | +1,19% |
| 1 Woche | 173,82€ | +3,10% |
| 1 Monat | 164,14€ | +9,17% |
| 6 Monate | 158,80€ | +12,84% |
| Lfd. Jahr (YTD) | 174,17€ | +2,89% |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 179,20€ |
| Eröffnung | 179,20€ |
| Geld | 178,00€ |
| Brief | 179,15€ |
| Tages-Hoch | 179,20€ |
| Tages-Tief | 179,20€ |
| 52 Wochen-Hoch | 180,50€ |
| 52 Wochen-Tief | 111,00€ |
| Allzeit-Hoch | 180,50€ |
| Allzeit-Tief | 111,00€ |
Nachrichten
- BUSINESS WIRE: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - 23.04.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Shareholders Approve All Annual General Meeting Proposals - 22.04.2026, 17:45:02 Uhr
- BUSINESS WIRE: Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform - 16.04.2026, 07:00:02 Uhr
- BUSINESS WIRE: Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause - 09.04.2026, 07:00:05 Uhr
- BUSINESS WIRE: AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis - 28.03.2026, 16:00:03 Uhr
- BUSINESS WIRE: AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs - 24.03.2026, 07:00:05 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing - 23.03.2026, 07:00:05 Uhr
- BUSINESS WIRE: Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting - 20.03.2026, 06:55:01 Uhr
- BUSINESS WIRE: AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies - 17.03.2026, 07:00:06 Uhr
- BUSINESS WIRE: Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering - 11.03.2026, 07:00:05 Uhr
